A--License to the Intellectual Property (IP) for AlphaVax's proprietary Venezuelan Equine Encephalitis (VEE) -based RNA replicon particle (VRP) system

The U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, has a requirement in support of the Medical Countermeasures Systems (MCS) to procure a perpetual license to the Intellectual Property (IP) for AlphaVax's proprietary Venezuelan Equine Encephalitis (VEE) -based RNA replicon particle (VRP) system, including but not limited to, patents, rights in inventions (patentable or not), copyrights, trade secrets, mask works, rights in databases and collections, other rights in software, and know-how techniques and other data under the authority of FAR Subpart 6.302-1(a)(2)(ii)(A) and (B). The VRP candidate was developed by AlphaVax with Government and private funds; therefore, the Government has Government Purpose Rights to a portion of the IP, but no rights to the development performed with private funding, nor exclusive rights to technologies developed with Government funds. AlphaVax is the only known source that has improved the existing Government owned VRP technology. AlphaVax is the product developer and, as such, is the only company that has developed and qualified the small-scale manufacturing process and product release assays for this platform. It is estimated that it would cost the Government two (2) years in schedule delays to develop a similar process, while potentially infringing on the existing Alphavax IP. Therefore, a contract to procure the IP for the AlphaVax platform would avoid schedule delays and reduce the research and development risk involved in attempting to develop a separate system. Interested parties may identify their interest and capability to respond to this requirement to the U.S. Army RDECOM Contracting Center, Natick Contracting Division via e-mail to: [email protected] no later than 9:00 a.m. on June 23, 2014.